Literature DB >> 17763173

Continuous hemodiafiltration in the treatment of hyperammonemia due to methylmalonic acidemia.

Chen-Yin Chen1, Tsung-Chang Tsai, Wei-Jen Lee, Hung-Chun Chen.   

Abstract

Methylmalonic academia (MMA) is a rare inborn error of branched-chain amino acid metabolism. Therapy consists of a special formulated protein diet, carnitine supplementation, and emergent detoxification during acute decompensation. Continuous hemodiafiltration is a modality choice to treat acute metabolic decompensation in inborn error of metabolism. We report the successful use of continuous hemodiafiltration in the management of acute decompensation in patients with methylmalonic academia. Three male patients were diagnosed with methylmalonic academia with the initial presentation of hyperammonemia. Continuous hemodiafiltration was utilized to treat acute decompensation of metabolic crisis. This approach results in a rapid reduction of systemic toxin levels. Continuous hemodiafiltration should be considered as a treatment modality for symptomatic neonates with MMA where hemodialysis is not feasible.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17763173     DOI: 10.1080/08860220701460426

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  2 in total

1.  Short-term survival of hyperammonemic neonates treated with dialysis.

Authors:  Stefano Picca; Carlo Dionisi-Vici; Andrea Bartuli; Tommaso De Palo; Francesco Papadia; Giovanni Montini; Marco Materassi; Maria Alice Donati; Enrico Verrina; Maria Cristina Schiaffino; Carmine Pecoraro; Emilia Iaccarino; Enrico Vidal; Alberto Burlina; Francesco Emma
Journal:  Pediatr Nephrol       Date:  2014-09-04       Impact factor: 3.714

2.  Continuous Renal Replacement Therapy for Treatment of Severe Attacks of Inborn Errors of Metabolism.

Authors:  Ayse Filiz Yetimakman; Selman Kesici; Murat Tanyildiz; Benan Bayrakci
Journal:  J Pediatr Intensive Care       Date:  2019-03-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.